Although CD40 mAbs have not achieved substantial single-agent anti-tumor activity, except for melanoma, combination with chemotherapy, radiotherapy, or immunotherapy has resulted in tumor regression in different cancer types [54]. This evidence concerns the gene CD40 and neoplasm.